{"schema_version":"secwatch.filing_event.v1","accession":"0001619856-25-000014","form_type":"8-K","ticker":"CRBU","cik":"0001619856","company_name":"Caribou Biosciences, Inc.","filed_at":"2025-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.212075+00:00","generated_at":"2026-05-25T01:33:12.452042+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Caribou Biosciences Q4/FY2024 net loss $149.1M; cash $249.4M into H2 2026; CSO retiring","bullets":["Net loss $149.1M in 2024 vs $102.1M in 2023; revenue fell to $10.0M from $34.5M on AbbVie deal end.","Cash, equivalents & marketable securities $249.4M at Dec 31, 2024, funding operations into H2 2026.","CB-010 ANTLER and CB-011 CaMMouflage Phase 1 clinical data expected in H1 2025.","CSO Steve Kanner to retire end of June 2025; no replacement planned; functions split among execs.","CFO Sri Ryali appointed in January 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001619856-25-000014","json":"https://secwatch.observer/filing/0001619856-25-000014.json","markdown":"https://secwatch.observer/filing/0001619856-25-000014.md","text":"https://secwatch.observer/filing/0001619856-25-000014.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1619856/000161985625000014/0001619856-25-000014-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1619856/000161985625000014/crbu-20250310.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T01:33:12.452042+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}